Affimed
 
   
 
     
 
     
  Management Team

Experienced and accomplished team of leaders
with proven track record
.
Manager
 
     
 
  Management Team of Affimed  
   
 
 
  Dr. Adi Hoess
Chief Executive Officer
Dr. Florian Fischer
Chief Financial Officer
Dr. Martin Treder
Chief Scientific Officer
Dr. Wolfgang Fischer
Chief Operating Officer
Dr. Leila Alland
Chief Medical Officer
 
 
 
 
   

 

Dr. Adi Hoess

  Chief Executive Officer
 
Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 has led the company as CEO. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to joining Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and CEO of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 – 2002 Dr. Hoess was General Manager and VP of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, VP of Licensing and BD.

Dr. Hoess received his PhD in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 Dr Hoess work as a post doc at the Dana-Farber Cancer Institute at the Harvard Medical School in Boston, USA.
 
   

 

Dr. Martin Treder

  Chief Scientific Officer
 
Starting his position in January 2015 Dr. Treder is responsible for the further development of Affimed’s proprietary bi- and trispecific TandAb platforms, the expansion of the company’s internal pipeline and furthermore providing scientific support for its clinical programs and for collaborations with corporate partners.

Dr. Treder has 13 years of professional experience in the field of biotherapeutic research and development and broad experience in immuno-oncology discovery and pre-clinical development of antibodies. He joined the Affimed Management Team from CT Atlantic AG, a Swiss biotechnology company focused on the identification and development of human-derived monoclonal antibodies for the treatment of cancer. As co-founder and Chief Scientific Officer he was responsible for establishing a broad research pipeline of various preclinical and clinical development programs.

Prior to CT Atlantic Dr. Treder was co-founder of U3 Pharma AG, a German biotech company developing targeted cancer therapeutics, and held the position of Program Director where he was responsible for heading the company’s portfolio of innovative anti-HER3 therapeutic antibodies. 

Dr. Treder graduated with Honors from Monash University in Melbourne, Australia and obtained a diploma in Biology at the  University of Würzburg, Germany. He earned his PhD working in Prof. Axel Ullrich's group at the Max Planck Institute of Biochemistry in Martinsried-Munich, Germany.
 
   

 

Dr. Florian Fischer
MBA (Dipl.-Kfm.)

  Chief Financial Officer
 
Dr. Fischer joined Affimed in 2005 as CFO on a part-time basis. Since September 2014, Dr. Fischer is fulltime employed by Affimed. He has a strong track record in various Biotech/MedTech executive positions, as lead advisor in a variety of transactions and financings in the life sciences and healthcare sector.

Dr. Fischer is founder of MedVenture Partners - a corporate finance and strategy advisory company focusing on the life sciences and healthcare industry. Dr. Fischer was Chief Financial Officer of Activaero GmbH from 2002 until 2011 and responsible for corporate development until the acquisition by Vectura in 2014. He also served as Chief Financial Officer of Vivendy Ltd. from 2008 until 2013 and as managing director of AbCheck in 2009. Prior to founding MedVenture Partners, Dr. Fischer worked with KPMG for more than six years until 2002, where he was responsible for biotech and healthcare assignments. Before joining KPMG, he worked for Deutsche Bank AG. Dr. Fischer is also a Director of Amphivena.

He holds a graduate degree in business administration from Humboldt University, Berlin and a Ph.D. in public health from the University of Bielefeld.
 
   

 

Dr. Wolfgang Fischer

  Chief Operating Officer
 
Dr. Wolfgang Fischer joined the Company in 2017 from Sandoz Biopharmaceuticals (Novartis Group). He has 20 years of experience in research and drug development with a focus on oncology, immunology and pharmacology. At Sandoz he managed the development and registration of Sandoz’ biosimilar pipeline assets since 2012 and served as Global Head of Program and Project Management since 2014. Prior to joining Sandoz, he held various positions of increasing responsibility within the Novartis Group since 2003, including Medical Director Oncology for Novartis Pharma Switzerland AG as well as Regional Medical Director Hematology (Emerging Growth Markets), where he was responsible for the Hematology Medical Affairs program and supported the launch of several products in various countries.

Wolfgang Fischer holds a Ph.D. in Cancer Research from the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. Thereafter, he completed postdoctoral fellowships at the Swiss Institute of Experimental Cancer Research, Lausanne, Switzerland and at the Scripps Research Institute, Department of Immunology, La Jolla, CA, USA, followed by a state doctorate (Habilitation) in Pharmacology and Toxicology at the Medical School of the University of Würzburg in Germany in 2003.
 
   

 

Dr. Leila Alland

  Chief Medical Officer
 
Dr. Leila Alland joined Affimed in 2018 as Chief Medical Officer responsible for the clinical strategy and execution of Affimed’s first-in-class NK and T cell engager programs through early and late stage clinical trials.  Dr. Alland brings to the Company over 20 years of experience in industry and academic research with a broad experience as a clinical leader developing both large and small molecule oncology products for solid and hematological malignancies, including Opdivo®, Tagrisso®, and Tasigna®.  Dr. Alland most recently served as CMO of Tarveda Therapeutics, developing targeted drug conjugates for solid tumors.  Prior to that, she was Vice President and Head of Oncology Early Clinical Development at AstraZeneca where she led Phase 1 and Phase 2 clinical development of oncology and immuno-oncology programs including a Phase 2 registration study that contributed to the accelerated approval of Tagrisso®. Previously, Dr. Alland served at Bristol-Myers Squibb as clinical head for multiple early phase oncology programs including immuno-oncology antibody therapeutics, and at Novartis where she led the clinical development program for Tasigna®.  Dr. Alland is also an experienced pediatric hematologist/oncologist and accomplished scientist, having served on the faculty at Albert Einstein College of Medicine, NY, where she was awarded the prestigious James S. McDonnell Foundation Scholar Award for research.

Dr. Alland completed her fellowship in pediatric hematology and oncology at Memorial Sloan Kettering Cancer Center, NY and her internship and residency at The Children’s Hospital of Philadelphia, PA.  She received her B.A. from the University of Pennsylvania and her M.D. from New York University School of Medicine.
 
 
 
     



 
  Impressum Disclaimer Data Privacy